Nature, Published online: 15 July 2026; doi:10.1038/s41586-026-10786-z
Chimeric antigen receptor (CAR) T cells for antitumour therapy ‘armoured’ with a dominant-negative TGFβ receptor II show enhanced efficacy and tolerable safety in patients with advanced hepatocellular carcinoma who have developed resistance or not responded to previous treatment.GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
Nature, Published online: 15 July 2026; doi:10.1038/s41586-026-10786-zChimeric antigen receptor (CAR) T cells for antitumour therapy ‘armoured’ with a dominant-negative TGFβ receptor II show enhanced efficacy and tolerable safety in pa…